logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11673902 B1

PDFFull Text
Date of Patent:
Jun. 13, 2023

Filed:

Jun. 17, 2022

Isoindolinone and indazole compounds for the degradation of egfr

Applicant:

C4 Therapeutics, Inc., Watertown, MA (US);

Inventors:

Christopher G. Nasveschuk, Stoneham, MA (US);

Martin Duplessis, Somerville, MA (US);

Jae Young Ahn, Somerville, MA (US);

Alexander W. Hird, Belmont, MA (US);

Ryan E. Michael, Erie, CO (US);

Kiel Lazarski, Boston, MA (US);

Yanke Liang, Belmont, MA (US);

Georg Jaeschke, Basel, CH;

Antonio Ricci, Biel-Benken, CH;

Annick Goergler, Colmar, FR;

Daniel Rueher, Raedersdorf, FR;

Assignee:

C4 Therapeutics, Inc., Watertown, MA (US);

Attorney:

Knowles Intellectual Property Strategies, LLC

Primary Examiner:

Genevieve S Alley

Int. Cl.
CPC ...
C07D 519/00 (2006.01); A61K 47/32 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 9/02 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 519/00 (2013.01); A61K 9/009 (2013.01); A61K 9/02 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/485 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); C07D 487/04 (2013.01);
Abstract

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

Find Patent Forward Citations

Nasveschuk, Christopher. (2023). Isoindolinone and indazole compounds for the degradation of egfr (U.S. Patent No. 11673902). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11673902

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…